People taking a widely used group of drugs known as calcium channel blockers to treat high blood pressure also appear to be cutting their risk of Parkinson’s disease, according to a study published in the February 6, 2008, online issue of Neurology.
The study involved 7,374 men and women over age 40. Half of the group had Parkinson’s disease; the other half did not have Parkinson’s disease. Among both groups, nearly half used high blood pressure medications, such as calcium channel blockers, ACE inhibitors, AT II antagonists and beta blockers.
The study found people who were currently long-term users of calcium channel blockers to treat high blood pressure lowered their risk of Parkinson’s disease by 23 percent compared to people who didn’t take the drugs. There was no such effect among people taking ACE inhibitors, AT II antagonists and beta blockers.
“Long-term use of calcium channel blockers was associated with a reduced risk of developing Parkinson’s disease while no such association was seen for other high blood pressure medicines,” said study author Christoph R. Meier, PhD, MSc, with University Hospital Basel in Switzerland.
Meier says more research is needed to determine why calcium channel blockers appear to protect against Parkinson’s disease, whether this is indeed a causal association, and why the other high blood pressure medications do not offer a reduced risk.
Source: American Academy of Neurology
Related stories:
Reaching 100 Is Easier Than Suspected
A healthy lifestyle during the early elderly years—including weight management, exercising regularly and not smoking—may be associated with a greater probability of living to age 90 in men, as well as good health and physical function, according to a report in the February 11 issue of
Archives of Internal Medicine.
Area of brain controlling the body’s response to exercise identified
The part of the brain which prepares our bodies for exercise, and controls our circulation and breathing while we exercise, has been identified by Oxford researchers.
Not so contoversial anymore -- panel says moderate coffee drinking reduces many risks
Although the American Society for Nutrition’s popular “controversy session” at Experimental Biology 2007 focuses on the health effects of coffee drinking, panel chair Dr. James Coughlin, a toxicology/safety consultant at Coughlin & Associates, says that recent advances in epidemiologic and experimental knowledge have transformed many of the negative health myths about coffee drinking into validated health benefits.
Drug reduces daily 'off' time for Parkinson patients
Parkinson disease patients taking the drug, ropinirole 24-hour prolonged release significantly reduced their daily "off" time in which Parkinson's symptoms like tremor, slowness, stiffness, and walking difficulty return as drugs wear off, according to a study published in the April 3, 2007, issue of
Neurology, the scientific journal of the American Academy of Neurology.
Nutrients might prevent hearing loss, new animal study suggests
Soldiers exposed to the deafening din of battle have little defense against hearing loss, and are often reluctant to wear protective gear like ear plugs that could make them less able to react to danger. But what if a nutritious daily "candy bar" could prevent much of that potential damage to their hearing?
Why dopamine freezes parkinson patients and drives drug addicts
Parkinson's disease and drug addiction are polar opposite diseases, but both depend upon dopamine in the brain. Parkinson's patients don't have enough of it; drug addicts get too much of it. Although the importance of dopamine in these disorders has been well known, the way it works has been a mystery.
Blood-related genetic mechanisms found important in Parkinson's disease
What does the genetics of blood cells have to do with brain cells related to Parkinson's disease? From an unusual collaboration of neurologists and a pharmacologist comes the surprising answer: Genetic mechanisms at play in blood cells also control a gene and protein that cause Parkinson's disease.
Baxter may stay out of Heparin business
The head of Baxter International Inc. said the company has not decided whether it will resume selling the blood thinner heparin in the United States.